Atrial cardiomyopathy (ACM) is a key independent predictor of stroke. The LeAAPS Trial integrates ACM factors to identify high-risk cardiac surgery patients who may benefit from preventative left atrial appendage exclusion.
Learn more about the trial: <a href="https://okt.to/ViH3OM" target="_blank">https://okt.to/ViH3OM</a>
<a href='https://www.linkedin.com/feed/hashtag/?keywords=CardiacSurgery&highligh…; target='_blank'>#CardiacSurgery</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=Stroke&highlightedUpdat…; target='_blank'>#Stroke</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=ClinicalTrial&highlight…; target='_blank'>#ClinicalTrial</a>
- Healthcare Professionals
- Therapies and Procedures
- Concomitant Surgical Ablation Therapy
- Ablation Sensing Unit & Switch Matrix
- cryoFORM® Cryoablation Probe
- cryoICE® BOX V6
- cryoICE® Cryoablation Probes
- Isolator® Linear Pen
- Isolator® Synergy™ Access® Clamp
- Isolator® Synergy™ Clamps (OLL2/OSL2)
- Isolator® Transpolar Pen (MAX3)
- Isolator® Synergy™ EnCompass® Clamp
- Multifunctional Ablation Generator (MAG)
- Hybrid AF™ Therapy
- Hybrid Total Thoracoscopic Therapy
- Left Atrial Appendage Management
- Cryo Nerve Block Therapy
- Concomitant Surgical Ablation Therapy
- Education & Training
- Clinical Evidence
- Product Labeling
- Resources
- Society Guidelines
- Therapies and Procedures
- Patients & Caregivers
- About AtriCure